LAWRENCEVILLE, N.J.,
Oct. 7, 2014 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN) is saddened to announce
the passing of Max E. Link, Ph.D., a
Director and the Chairman of the Board of Directors of the
Company. Dr. Link passed away unexpectedly at the age of
74.
Michael H. Tardugno, President
and Chief Executive Officer of Celsion, stated, "Max was a pillar
in the pharmaceutical industry – a visionary who believed in the
transformative power of science to positively impact human
health. His contributions over the course of his
distinguished career will leave a lasting legacy, and all of us at
Celsion are indebted to him for his leadership, support and
friendship. We are deeply saddened and mourn his loss."
Dr. Link served on Celsion's Board of Directors since 1997 and
as Chairman of the Board since 2001. The Board of Directors
has begun the process to identify qualified candidates to fill the
vacancy on the Board.
During Dr. Link's distinguished career, he served in
numerous positions with Sandoz Pharmaceuticals (now part of
Novartis), culminating in his appointment as Chairman of its Board
of Directors in 1992. From 1993 to 1994, Dr. Link served as
Chief Executive Officer of Corange, Ltd., the parent company
of Boehringer Mannheim Therapeutics, Boehringer Mannheim
Diagnostics and DePuy Orthopedics. From 2001 to 2003,
Dr. Link served as Chairman and Chief Executive Officer of
Centerpulse AG, a medical implant company. Dr. Link
also served on the Board of Directors of numerous development stage
companies within the biopharmaceutical and medical device fields,
both private and public companies.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer.
The pipeline also includes EGEN-001, a DNA-based immunotherapy for
the localized treatment of ovarian and brain cancers. Celsion
has three platform technologies for the development of novel
nucleic acid-based immunotherapies and other anti-cancer DNA or RNA
therapies, including TheraPlas™, TheraSilence™ and RAST ™.
For more information on Celsion, visit our website:
http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements
in this release are made pursuant to the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995.
Readers are cautioned that such forward-looking statements involve
risks and uncertainties including, without limitation, unforeseen
changes in the course of research and development activities and in
clinical trials; the uncertainties of and difficulties in analyzing
interim clinical data, particularly in small subgroups that are not
statistically significant; FDA and regulatory uncertainties and
risks; the significant expense, time, and risk of failure of
conducting clinical trials; the need for Celsion to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses or the possible failure to
make such acquisitions or licenses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in the Celsion's periodic reports and
prospectuses filed with the Securities and Exchange
Commission. Celsion assumes no obligation to update or
supplement forward-looking statements that become untrue because of
subsequent events, new information or otherwise.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
SOURCE Celsion Corporation